Board summary
Key figures
45,544
Registered population
65.2% aged 18–64
12.8%
Aged 65+
ICB 19.0% · England 17.9%
21.8%
Ethnic minority (non-White)
5.9% Asian · England 9.6%
78.5%
In IMD quintile 1
ICB 31.9% · England 21.0%
~28,097
Core20 residents (est.)
Resident basis; registered basis ~36,251 · see page 3
6,362
Hypertension register
+3.95% in 3 yrs · England +5.60%
781
SMI register
9.3% of Liverpool (LAD)'s
1,540
COPD register
Reviews -7.95% in 3 yrs
Forecast to 2030
7,146
Hypertension patients, 2030
+784 on today
66.5%
QRISK ≥20% on statins, 2030
-0.13pp over 3 yrs
3.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Chronic disease annual reviews fell sharply.
Heart failure reviews fell 42.6% over 2023 to 2025 to 51.8% (England 78.5%), and asthma reviews fell 14.0%, leaving 816 patients unreviewed.
Age-five MMR2 and booster coverage lag.
Age-five MMR2 reaches 62.2% (England 82.8%, 32.8 pp below the 95.0% target) and the 4-in-1 booster is 56.7% (England 80.9%) in Q1 2025/26.
Cardiovascular lipid and BP control exceed England.
Lipid-lowering therapy reaches 66.8% for QRISK ≥ 20% (England 63.6%) and 76.6% in CKD (England 70.3%), while hypertension treatment to target is 70.7%.
Population, age and ethnicity
Younger list with 12.8% aged 65+ and 21.8% ethnic minority residents may shape demand
Liverpool First PCN serves 45,544 registered patients across 10 practices, with lists ranging from 2,177 at GP Practice Riverside (dr Jude) to 9,084 at Dr Jude's Practice - Riverside. Patients aged 0-17 make up 22.1%, above Liverpool (19.8%), the ICB (19.2%) and England (19.6%), whereas those aged 65+ represent 12.8%, below Liverpool (15.6%), the ICB (19.0%) and England (17.9%). Census data for associated resident areas shows 78.2% White residents (Liverpool 84.0%; ICB 93.0%; England 81.1%) and a 21.8% ethnic minority share, including 6.2% Black and 5.9% Asian residents. Ethnicity figures reflect area residents rather than registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 cohort share reaches 78.5% with five practices at 100.0% concentration
The PCN Core20 cohort is 78.5%, exceeding Liverpool (54.9%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 2.2. Practice estimates sum to 36,251 Core20 patients, whereas resident deciles 1+2 estimate 28,097; these different denominators must be reconciled before targeting. Across the PCN, five practices each show a 100% Core20 share. Meanwhile, Dr Jude's Practice - Riverside records a Core20 cohort of 90.0%, representing 8,177 estimated Core20 patients. Targeting could combine whole-practice outreach for the former group with caseload support for the latter.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
781
SMI register
1.69% recorded prevalence
523
Learning disability register
1.13% recorded prevalence
24
Care homes, 1,210 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
Learning disability prevalence is 1.1% (523 patients) and severe mental illness is 1.7% (781 patients), both above Liverpool (0.6% and 1.4%), the ICB (0.6% and 1.1%) and England (0.6% and 1.0%). Catchment care homes total 24 with 1,210 beds, though resident occupancy is unconfirmed. With both inclusion-health registers above England rates, prioritising annual health checks for these cohorts is the key workload to protect.
Severe mental illness: physical health checks
Severe mental illness blood pressure check coverage is 77.2% (England 83.4%), falling 3.3 pp over 2023 to 2025 while England rose +4.4 pp. BMI checks fell 0.8 pp (England +5.1 pp) to 81.7%, requiring proactive physical health review.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,362
Hypertension register
+3.95%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+1.35pp
BP control, under 80
≤140/90 · −1.75pp aged 80+
+784
More patients by 2030
Forecast 7,146 (14.84%)
Hypertension case-finding and control
Hypertension prevalence is 13.7% (6,362 patients), below England (15.2%), Liverpool (14.0%) and the ICB (16.8%). Patients treated to target reach 70.7% (England 70.3%). However, recent blood pressure readings fell 0.8 pp over 2023 to 2025 (England +3.1 pp) to 86.7% (England 90.0%), blood pressure control at age 80+ fell 1.8 pp (England +1.8 pp) to 80.2% (England 81.2%), and annual heart failure reviews dropped 42.6% (England +8.7%) to 51.8% (England 78.5%). Lower crude prevalence could reflect age profile (12.8% aged 65+), which age-standardisation would test. Monitoring and older-adult control lag national benchmarks, indicating proactive recall should be prioritised.
Lipids and statins
Lipid coverage reaches 66.8% for QRISK 20% and over (England 63.6%) and 76.6% in CKD (England 70.3%). However, diabetic primary statin coverage fell 3.6 pp over 2023 to 2025 (England +1.5 pp) to 72.1% (England 73.2%). Diabetic primary statin coverage trails national benchmarks, making a recall audit of eligible patients the immediate priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 77,949 | £1.60 | £1.71 | £1.86 | £124,718 |
| Cardiovascular (all), 2025 | 108,549 | £3.69 | £4.37 | £3.33 | £400,546 |
For lipid-regulating drugs in 2026, the PCN prescribed 77,949 items at £1.60 per item, below England (£1.86), Liverpool (£1.82), and the ICB (£1.71), spending £20,267 less than at England's unit cost. Unit spend is lower than England, offering headroom to review therapy without exceeding benchmark expenditure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−13.98%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.19%
Asthma prevalence, PCN 3-yr % change
COPD recorded prevalence is 3.3% (England 1.9%) across 1,540 patients, but annual reviews fell 8.0% over 2023 to 2025 (England +2.8%) to 77.3%. Asthma reviews fell 10.7 pp or 14.0% (England +2.8 pp or +4.4%) to 65.8%, leaving an estimated 816 patients unreviewed. Prescribing of asthma management items for ages 5-19 reaches 2,586 per 1,000 (England 1,488). Falling review coverage alongside high youth prescribing may reflect follow-up gaps, which practice-level audit would test.
Cancer register and children's immunisation
Cancer recorded prevalence is 2.8% across 1,272 patients (England 3.8%). Childhood immunisation coverage in Q1 2025/26 trails national benchmarks across all milestones: 6-in-1 at 12 months is 82.4% (England 91.0%). By age 5, MMR1 reaches 74.0% but MMR2 is 62.2% (England 82.8%, 32.8 pp below the 95.0% target), an 11.8 pp dose difference, while 4-in-1 booster coverage is 56.7% (England 80.9%), which may leave preschool vulnerability, which clinical audit would verify.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) and up 2.6 pp from 52.8% in 2013 (distance to the 75.0% national ambition by 2028: -19.5 pp; about 2,640 extra early diagnoses required annually). Known-stage coverage was 72.8% (13,490 of 18,522 registered cancers). These ICB figures describe the wider system, not PCN performance. Primary care screening remains low: the PCN achieves 56.5% cervical screening coverage (England 66.8%) and 56.1% breast screening coverage (England 69.9%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Liverpool University Hospitals NHS Foundation Trust, 73.2574% of patients met the 62-day referral to treatment standard (distance to the 85.0% standard: -11.7 pp). The trust reached 75.4716% on the 28-day faster diagnosis standard (distance: 0.5 pp against 75.0%) and 90.5077% on the 31-day combined standard (distance to 96.0%: -5.5 pp). Across NHS Cheshire and Merseyside Integrated Care Board, 62-day waits reached 76.232% (distance: -8.8 pp), 28-day diagnosis reached 77.2451% (distance: 2.2 pp), and 31-day treatment was 95.7087% (distance: -0.3 pp). These trust and ICB figures describe the wider system, not PCN performance.
| Pathways within standard (%) | Liverpool | Mersey and West Lancashire | Wirral | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.47 | 72.39 | 74.71 | 77.25 | 79.32 |
| 31-day treatment (96%) | 90.51 | 95.46 | 92.53 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 73.26 | 77.96 | 77.65 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Liverpool | Mersey and West Lancashire | Wirral | England |
|---|---|---|---|---|
| MRI | 6.42 | 14.04 | 1.54 | 21.40 |
| CT | 0.71 | 13.08 | 1.55 | 9.92 |
| Echocardiography | 12.55 | 34.88 | 5.07 | 28.48 |
| Colonoscopy | 33.14 | 18.04 | 32.81 | 30.83 |
| Gastroscopy | 44.99 | 18.17 | 17.73 | 29.02 |
| All 15 DM01 tests | 11.50 | 21.17 | 5.02 | 23.14 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), adults aged 65 and over accounted for 65.4% of community contacts among Liverpool residents (83,300 of 127,380 total contacts). These borough-level resident figures describe wider system activity rather than PCN-specific contacts.
Practice variation and patient experience
Inter-practice phone access spans 45.6 pp and good experience varies by 36.2 pp
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Stopgate Lane | 111 | 44.9 | 76.9% | 66.1% | 93.1% |
| Hornspit | 121 | 43.9 | 71.4% | 61.1% | 92.7% |
| Walton Village | 99 | 100.0 | 80.5% | 75.0% | 91.5% |
| Sandringham | 107 | 56.5 | 68.6% | 74.8% | 81.5% |
| Benim | 121 | 100.0 | 41.1% | 74.5% | 69.6% |
| Dr Jude's - | 94 | 90.0 | 40.6% | 83.4% | 64.8% |
| Yew Tree Centre | 99 | 71.6 | 34.9% | 72.2% | 62.6% |
| Abingdon Family | 109 | 100.0 | 39.4% | 71.3% | 61.5% |
| GP Riverside (dr | 80 | 100.0 | 36.7% | 78.2% | 58.6% |
| Bigham Road | 87 | 100.0 | 43.1% | 61.1% | 56.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 measures, 23 trail England's three-year change, led by falling reviews
Across 25 tracked measures, 23 trail England's three-year change. The sharpest lags sit in annual chronic disease reviews: heart failure reviews fell 42.6% over 2023 to 2025 (England +8.7%), asthma reviews fell 14.0% (England +4.4%), and COPD reviews fell 8.0% (England +2.8%). In contrast, breast screening coverage grew +26.3% over 2023 to 2024 (England +8.4%), and cervical screening fell 0.2% over 2023 to 2025 (England -1.0%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
Dementia register
COPD register
Breast screening (53-70)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 24 (1,210 beds) | n/a | Schools (catchment) | 149 | n/a |
| Children's centres | 9 | 26 | Places of worship | 71 | 240 |
| Libraries | 4 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 23 | 91 | Primary academies | 6 | 20 |
| Special schools | 1 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review and inhaler recall
Asthma review coverage is 65.8% across 2,383 patients (England 65.7%; Liverpool 64.3%), falling 14.0% (or 10.7 pp) over 2023 to 2025 (England +4.4%; +2.8 pp), leaving 816 unreviewed. For discussion: practices could run structured asthma recall pairing annual review templates with inhaler prescribing checks and after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
Across 781 SMI patients (1.7% prevalence vs England 1.0%), annual blood pressure checks fell 3.3 pp over 2023 to 2025 (England +4.4 pp) to 77.2% (England 83.4%; Liverpool 79.8%). For discussion: practices could audit SMI physical check recording, offer combined outreach appointments and raise data-sharing pathways with system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Preschool MMR2 and booster recall
In Q1 2025/26, age-5 MMR2 coverage is 62.2% (England 82.8%, 32.8 pp below 95.0%, 11.8 pp below MMR1 at 74.0%) and 4-in-1 booster coverage is 56.7% (England 80.9%, 38.3 pp below 95.0%). Moderate effort to run.
Evidence base: size of the 0–17 cohort: the population for primary immunisation schedule (8, 12 and 16 weeks) and 1-year boosters including MMR dose 1, 2–2.5-year health visiting review, school-based childhood flu vaccination, HPV (12–13), MenACWY and Td/IPV (14) immunisation and new-birth, 6–8 week and 12-month health visiting reviews.
Policy anchor: Mental health support teams: 77% coverage in 2026/27, 94% by 2028/29, 100% by 2029; Health and Wellbeing Boards must develop neighbourhood health plans for 2027/28 during 2026/27.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Ethnicity recording and access review (p2) | White | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension monitoring and recall (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster and MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Access and patient experience review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Preschool MMR2 and booster recall (p12) | Aged 0-17 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
